Who are IL-17A antibody's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Taltz, Cosentyx, Ixekizumab Prefilled Syringe, Vunakizumab (IL-17A inhibitor), Secukinumab Auto-Injector, Subcutaneous injection of Secukinumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/il-17a-antibody.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

IL-17A antibody — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IL-17A antibody (IL-17A antibody) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-IL-17 monoclonal antibody. Area: Immunology.

phase 2 Anti-IL-17 monoclonal antibody IL-17A Immunology Biologic Live · refreshed every 30 min

Target snapshot

IL-17A antibody (IL-17A antibody) — Genrix (Shanghai) Biopharmaceutical Co., Ltd.. IL-17A antibody targets the IL-17A receptor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IL-17A antibody TARGET	IL-17A antibody	Genrix (Shanghai) Biopharmaceutical Co., Ltd.	phase 2	Anti-IL-17 monoclonal antibody	IL-17A
Taltz	ixekizumab	Eli Lilly	marketed	Interleukin-17A antagonist	Interleukin 17A (IL-17A) cytokine	2016-01-01
Cosentyx	secukinumab	Novartis	marketed	IL-17A antagonist	Interleukin-17A (IL-17A)	2015-01-01
Ixekizumab Prefilled Syringe	Ixekizumab Prefilled Syringe	Eli Lilly and Company	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Vunakizumab (IL-17A inhibitor)	Vunakizumab (IL-17A inhibitor)	Fujian Cancer Hospital	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Secukinumab Auto-Injector	Secukinumab Auto-Injector	University of Pennsylvania	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A
Subcutaneous injection of Secukinumab	Subcutaneous injection of Secukinumab	Peking Union Medical College	marketed	IL-17A inhibitor (monoclonal antibody)	IL-17A (Interleukin-17A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-IL-17 monoclonal antibody class)

Genrix (Shanghai) Biopharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IL-17A antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/il-17a-antibody. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing